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295 Reorganization of cytoskeletal proteins and prolonged life expectancy caused
by hepatocyte growth factor in a hamster model of late-phase dilated
cardiomyopathy
Haruhiko Kondoh, MD, Yoshiki Sawa, MD, Norihide Fukushima, MD, Goro Matsumiya, MD,
Shigeru Miyagawa, MD, Satoru Kitagawa-Sakakida, MD, Imran A. Memon, MD,
Naomasa Kawaguchi, MD, Nariaki Matsuura, MD, and Hikaru Matsuda, MD, Osaka, Japan
HGF treatment induced transient re-expression of alpha-dystroglycan and alpha- and beta-
sarcoglycan and reduced fibrosis in the myocardium of 27-week-old TO-2 hamsters.
Deterioration of cardiac performance was delayed; the survival of HGF-treated hamsters at 40
weeks was 84.2%, whereas that of control hamsters was 43.8%.
303 Increased prothrombotic state lasting as long as one month after on-pump
and off-pump coronary surgery
Alessandro Parolari, MD, PhD, Luciana Mussoni, PhD, Marta Frigerio, PhD,
Moreno Naliato, MD, Francesco Alamanni, MD, Andrea Galanti, MD, Giuseppe Fiore, MD,
Fabrizio Veglia, PhD, Elena Tremoli, PhD, Paolo Biglioli, MD, and
Marina Camera, Biol Sci, PhD, Milan, Italy
Follow-up of coagulation, fibrinolysis, and endothelial activation to 1 month after off- or on-
pump CABG shows that off-pump surgery somehow prevents intraoperative activation of
coagulatory and fibrinolytic pathways and of endothelium. During midterm follow-up, however,
the prothrombotic and inflammatory patterns are similar.
309 Tranexamic acid and early saphenous vein graft patency in conventional
coronary artery bypass graft surgery: A prospective randomized controlled
clinical trial
Jacek Karski, MD, George Djaiani, MD, Jo Carroll, RN, Mark Iwanochko, MD,
Priya Seneviratne, MD, Peter Liu, MD, Walter Kucharczyk, MD, Ludwik Fedorko, MD,
Tirone David, MD, and Davy Cheng, MD, Toronto, Ontario, Canada
Our prospective randomized clinical trial involving 312 patients undergoing conventional
coronary revascularization surgery has demonstrated that the administration of tranexamic acid
before cardiopulmonary bypass does not seem to compromise venous graft patency rates;
consequently, it could be advocated for routine use in this patient population.
315 A comparison of transit-time flowmetry and intraoperative fluorescence
imaging for assessing coronary artery bypass graft patency
Lognathen Balacumaraswami, FRCS, Yasir Abu-Omar, MRCS, Bikram Choudhary, MRCS,
David Pigott, FRCA, and David P. Taggart, MD, PhD, FRCS, Oxford, United Kingdom
We prospectively assessed intraoperative graft patency by using both intraoperative
fluorescence imaging and transit-time flowmetry (TTFM) in 100 patients and found that
although in most patients both systems confirmed graft patency, in a small proportion (10%) of
patients, assessment with TTFM alone might lead to unnecessary graft revision.
Table of Contents (continued)
(continued on page 18A)
16A The Journal of Thoracic and Cardiovascular Surgery ● August 2005
ED
ITO
RIA
L
CH
D
CSP
G
TS
ET
A
CD
TX
